CHMP gives nod to EUSA Pharma's Zenas
This article was originally published in Scrip
Executive Summary
The CHMP has issued a positive opinion on EUSA Pharma SAS's lead compound, Zenas (amifampridine), for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS).